Evaluation and Comparison of Two Novel Non-Platinum-Based Antitumor Agents on Pancreatic Cancer and Triple-Negative Breast Cancer
Loading...
Date
2022-10-03
Authors
Xu, Xiangxuan
Journal Title
Journal ISSN
Volume Title
Publisher
University of Waterloo
Abstract
Cancer is one of the leading causes threatening human life. People suffering from pancreatic cancer and triple-negative breast cancer (TNBC) have particularly low survival rate among all cancer types. The novel non-platinum based antitumor agents, femtomedicine (FMD) compounds, were discovered as a new class of chemotherapeutic targeting agents to treat multiple cancers. Herein, two of the most effective FMD compounds (FMD-2Br-DAB & FMD-2I-DAB) were evaluated, based on their cytotoxicity against TNBC and pancreatic cancer cells through MTT assay, clonogenic assay, and caspase-3/7 green detection. According to the results obtained from these well-established cell-biology techniques, FMD compounds exhibit good antitumor effects in the cancer cell lines (PANC-1, BXPC-3, and MDA-MB-231), while having minimal impact on the normal cell line (GM05757), indicating FMD compounds can selectively kill TNBC and pancreatic cancer cells without being detrimental to normal cells. Furthermore, FMD-2I-DAB (compound C) shows a better efficiency than FMD-2Br-DAB (compound B), inferring that compound C could be more potent in tumor elimination. This study shows that the FMD compounds, especially for compound C, are potentially new drug candidates for effective treatment of the ‘hard-to-treat’ pancreatic cancer and TNBC.